Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Daunorubicin

SKU: orb2655790

Description

Daunorubicin is potent topoisomerase II (Topo II) inhibitor, interacts with DNA by intercalation and inhibition of macromolecular biosynthesis in cancer cells; Daunorubicin is a chemotherapy agent used to treat multiple cancer, secifically used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma; Daunorubicin and it's derivatives are widely used as payloads in antibody-drug conjugates (ADCs).Chemotherapeutic Agents Approved.

Images & Validation

Key Properties

CAS Number20830-81-3
MW527.5198
Purity>98% (HPLC)
FormulaC27H29NO10
SMILESCC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O
TargetADC Cytotoxin
Solubility10 mM in DMSO

Bioactivity

In Vivo
Daunorubicin (intravenous injection, 3 mg/kg, three times at 48 h intervals.) produces cardiotoxicity and nephrotoxicity in rats. Daunorubicin (intraperitoneal injection, 10 mg/kg) induces sister chromatid exchanges in mice. Animal model: Male Sprague-Dawley rats. Dosage: 3 mg/kg. Administration: Intravenous injection, three times at 48 h intervals. Result: Caused a significant increase in MDA (malondialdehyde) level in renal tissue, accompanied by a significant reduction in total GPx activity. Increased urinary protein excretion, serum creatinine, and BUN level.
In Vitro
Daunorubicin (0-256 μg/mL, 30 min) inhibits DNA and RNA synthesis in sensitive and resistant Ehrlich ascites tumor cells. Daunorubicin (7 nM-1.9 μM, 72 h) shows chemosensitivity in Molt-4 cells and L3.6 cells. Daunorubicin (0.4 μM, 48 h) induces apoptotic and necrosis in L3.6 cells. Daunorubicin (0.4 μM, 120 min) induces ROS generation in L3.6 cells. Daunorubicin (2 μM, 24 h) induces autophagy in K562 cells (myeloid cell line). Cell Viability Assay Cell line: Molt-4 cells (a human T-lymphoblastic leukemia cell line), L3.6 cells (metastatic human pancreatic cell line) Concentration: 7 nM-1.9 μM Incubation time: 72 h. Result: Inhibited cell viability with IC50 values of 40 nM (Molt-4) and 400 nM (L3.6). Apoptosis Analysis Cell line: L3.6 cells Concentration: 0.4 μM Incubation time: 24 h, 48 h. Result: Induced necrosis without apoptosis at 24 h, induced both an apoptotic and extensive necrotic response at 48 h. Western blot analysis. Cell line: K562 cells. Concentration: 2 μM. Incubation time: 24 h. Result: Enabled the switch of LC3-I into LC3-II, accompanied with a significant increased expression level of LC3.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

RP13057 | Daunomycin | Rubidomycin

Similar Products

  • ABCG2 Rabbit mAb [KD Validated] Antibody [orb1951231]

    WB

    Human

    Rabbit

    Monoclonal

    Unconjugated

    100 μl, 50 μl
  • Daunorubicin [orb611916]

    >98%

    20830-81-3

    527.526

    C27H29NO10

    100 mg, 1 g, 250 mg
  • drrB Antibody [orb813492]

    ELISA,  WB

    Bacteria

    Rabbit

    Polyclonal

    Unconjugated

    2 mg
  • drrA Antibody [orb812974]

    ELISA,  WB

    Bacteria

    Rabbit

    Polyclonal

    Unconjugated

    2 mg
  • Daunosamnyl-daunorubicin [orb1702379]

    28008-54-0

    656.68

    C33H40N2O12

    25 mg, 50 mg, 100 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Protocol Information